239 related articles for article (PubMed ID: 30428334)
21. Intranasal Delivery of Exendin-4 Confers Neuroprotective Effect Against Cerebral Ischemia in Mice.
Zhang H; Meng J; Zhou S; Liu Y; Qu D; Wang L; Li X; Wang N; Luo X; Ma X
AAPS J; 2016 Mar; 18(2):385-94. PubMed ID: 26689204
[TBL] [Abstract][Full Text] [Related]
22. Intranasal Delivery of Apelin-13 Is Neuroprotective and Promotes Angiogenesis After Ischemic Stroke in Mice.
Chen D; Lee J; Gu X; Wei L; Yu SP
ASN Neuro; 2015; 7(5):. PubMed ID: 26391329
[TBL] [Abstract][Full Text] [Related]
23. The erythropoietin-derived peptide MK-X and erythropoietin have neuroprotective effects against ischemic brain damage.
Yoo SJ; Cho B; Lee D; Son G; Lee YB; Soo Han H; Kim E; Moon C; Moon C
Cell Death Dis; 2017 Aug; 8(8):e3003. PubMed ID: 28817120
[TBL] [Abstract][Full Text] [Related]
24. Intranasal delivery of progesterone after transient ischemic stroke decreases mortality and provides neuroprotection.
Fréchou M; Zhang S; Liere P; Delespierre B; Soyed N; Pianos A; Schumacher M; Mattern C; Guennoun R
Neuropharmacology; 2015 Oct; 97():394-403. PubMed ID: 26079443
[TBL] [Abstract][Full Text] [Related]
25. Lectin-conjugated PEG-PLA nanoparticles: preparation and brain delivery after intranasal administration.
Gao X; Tao W; Lu W; Zhang Q; Zhang Y; Jiang X; Fu S
Biomaterials; 2006 Jun; 27(18):3482-90. PubMed ID: 16510178
[TBL] [Abstract][Full Text] [Related]
26. Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke.
Hanson LR; Roeytenberg A; Martinez PM; Coppes VG; Sweet DC; Rao RJ; Marti DL; Hoekman JD; Matthews RB; Frey WH; Panter SS
J Pharmacol Exp Ther; 2009 Sep; 330(3):679-86. PubMed ID: 19509317
[TBL] [Abstract][Full Text] [Related]
27. Inhibiting pro-death NMDA receptor signaling dependent on the NR2 PDZ ligand may not affect synaptic function or synaptic NMDA receptor signaling to gene expression.
Martel MA; Soriano FX; Baxter P; Rickman C; Duncan R; Wyllie DJ; Hardingham GE
Channels (Austin); 2009; 3(1):12-5. PubMed ID: 19221512
[TBL] [Abstract][Full Text] [Related]
28. Intranasal delivery of bFGF with nanoliposomes enhances in vivo neuroprotection and neural injury recovery in a rodent stroke model.
Zhao YZ; Lin M; Lin Q; Yang W; Yu XC; Tian FR; Mao KL; Yang JJ; Lu CT; Wong HL
J Control Release; 2016 Feb; 224():165-175. PubMed ID: 26774220
[TBL] [Abstract][Full Text] [Related]
29. Protective effects of the angiotensin II AT
Bennion DM; Jones CH; Dang AN; Isenberg J; Graham JT; Lindblad L; Domenig O; Waters MF; Poglitsch M; Sumners C; Steckelings UM
Clin Sci (Lond); 2018 Mar; 132(5):581-593. PubMed ID: 29500223
[TBL] [Abstract][Full Text] [Related]
30. TFP5 peptide, derived from CDK5-activating cofactor p35, provides neuroprotection in early-stage of adult ischemic stroke.
Ji YB; Zhuang PP; Ji Z; Wu YM; Gu Y; Gao XY; Pan SY; Hu YF
Sci Rep; 2017 Jan; 7():40013. PubMed ID: 28045138
[TBL] [Abstract][Full Text] [Related]
31. Dual targeted nanocarrier for brain ischemic stroke treatment.
Zhao Y; Jiang Y; Lv W; Wang Z; Lv L; Wang B; Liu X; Liu Y; Hu Q; Sun W; Xu Q; Xin H; Gu Z
J Control Release; 2016 Jul; 233():64-71. PubMed ID: 27142584
[TBL] [Abstract][Full Text] [Related]
32. Applications of Liposomal Drug Delivery Systems to Develop Neuroprotective Agents for the Treatment of Ischemic Stroke.
Fukuta T; Ishii T; Asai T; Oku N
Biol Pharm Bull; 2019; 42(3):319-326. PubMed ID: 30828062
[TBL] [Abstract][Full Text] [Related]
33. Tat-NR2B9c prevents excitotoxic neuronal superoxide production.
Chen Y; Brennan-Minnella AM; Sheth S; El-Benna J; Swanson RA
J Cereb Blood Flow Metab; 2015 May; 35(5):739-42. PubMed ID: 25669908
[TBL] [Abstract][Full Text] [Related]
34. Neuron protection as a therapeutic target in acute ischemic stroke.
Tuttolomondo A; Di Sciacca R; Di Raimondo D; Arnao V; Renda C; Pinto A; Licata G
Curr Top Med Chem; 2009; 9(14):1317-34. PubMed ID: 19849659
[TBL] [Abstract][Full Text] [Related]
35. Intranasal Delivery of Targeted Nanoparticles Loaded With miR-132 to Brain for the Treatment of Neurodegenerative Diseases.
Su Y; Sun B; Gao X; Dong X; Fu L; Zhang Y; Li Z; Wang Y; Jiang H; Han B
Front Pharmacol; 2020; 11():1165. PubMed ID: 32848773
[TBL] [Abstract][Full Text] [Related]
36. Neuroprotection after status epilepticus by targeting protein interactions with postsynaptic density protein 95.
Dykstra CM; Ratnam M; Gurd JW
J Neuropathol Exp Neurol; 2009 Jul; 68(7):823-31. PubMed ID: 19535989
[TBL] [Abstract][Full Text] [Related]
37. Tramiprosate protects neurons against ischemic stroke by disrupting the interaction between PSD95 and nNOS.
Wu S; Yue Y; Tian H; Tao L; Wang Y; Xiang J; Wang S; Ding H
Neuropharmacology; 2014 Aug; 83():107-17. PubMed ID: 24769446
[TBL] [Abstract][Full Text] [Related]
38. Stroke injury induced by distal middle cerebral artery occlusion is resistant to N-methyl-d-aspartate receptor antagonism in FVB/NJ mice.
Liu CW; Liao KH; Wu CM; Chen HY; Wang EY; Lai TW
Neuroreport; 2021 Sep; 32(13):1122-1127. PubMed ID: 34284452
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of the PSD95 inhibitor Tat-NR2B9c in mice requires dose translation between species.
Teves LM; Cui H; Tymianski M
J Cereb Blood Flow Metab; 2016 Mar; 36(3):555-61. PubMed ID: 26661213
[TBL] [Abstract][Full Text] [Related]
40. Targeted delivery of etoposide, carmustine and doxorubicin to human glioblastoma cells using methoxy poly(ethylene glycol)‑poly(ε‑caprolactone) nanoparticles conjugated with wheat germ agglutinin and folic acid.
Kuo YC; Chang YH; Rajesh R
Mater Sci Eng C Mater Biol Appl; 2019 Mar; 96():114-128. PubMed ID: 30606517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
